John Bridgewater leads the clinical trials portfolio of the National Cancer Research Institute (NCRI) Hepatobiliary group (ABC-02 paper NEJM1, New EPOC paper Lancet Oncology2). He founded the International Biliary Tract Cancer Collaborators group and leads the NCRI Genomics England programme for upper gastrointestinal cancers.
He is working on a series of multidisciplinary studies including a study with Henning Walczak (UCL CI) using multiple immune phenotype measurements to guide personalised, sequential immunotherapy in a phase 1 programme. Patients with a poor response to PD-1 inhibition will be treated with a tailored, novel combination of immunotherapies, the immune response to which will in turn be measured. Therapy will adapt dependent on longitudinal immunoprofile.
- Valle J, Wasan H, Palmer DH, et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N Engl J Med 2010; 362(14): 1273-81.
- Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15.